Geron Corp GERN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
3.80UNCH (UNCH)
Volume
178,193
Close
3.80quote price arrow down-0.08 (-2.06%)
Volume
4,176,014
52 week range
1.64 - 4.30
Loading...
  • Open3.92
  • Day High3.94
  • Day Low3.75
  • Prev Close3.88
  • 52 Week High4.30
  • 52 Week High Date04/29/24
  • 52 Week Low1.64
  • 52 Week Low Date03/13/24

Key Stats

  • Market Cap2.254B
  • Shares Out593.13M
  • 10 Day Average Volume10.95M
  • Dividend-
  • Dividend Yield-
  • Beta0.45
  • YTD % Change80.09

KEY STATS

  • Open3.92
  • Day High3.94
  • Day Low3.75
  • Prev Close3.88
  • 52 Week High4.30
  • 52 Week High Date04/29/24
  • 52 Week Low1.64
  • 52 Week Low Date03/13/24
  • Market Cap2.254B
  • Shares Out593.13M
  • 10 Day Average Volume10.95M
  • Dividend-
  • Dividend Yield-
  • Beta0.45
  • YTD % Change80.09

RATIOS/PROFITABILITY

  • EPS (TTM)-0.35
  • P/E (TTM)-10.97
  • Fwd P/E (NTM)-10.70
  • EBITDA (TTM)-209.532M
  • ROE (TTM)-60.04%
  • Revenue (TTM)519,999.981
  • Gross Margin (TTM)-
  • Net Margin (TTM)-38,729.81%
  • Debt To Equity (MRQ)23.99%

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Geron Corp

 

Profile

MORE
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical...
John Scarlett M.D.
Chairman of the Board, President, Chief Executive Officer
Andrew Grethlein Ph.D.
Executive Vice President, Chief Operating Officer
Michelle Robertson
Chief Financial Officer, Executive Vice President - Finance, Treasurer
Scott Samuels Esq.
Executive Vice President, Chief Legal Officer, Secretary
Melissa Behrs
Executive Vice President - Business Operations, Chief Alliance Officer
Address
919 East Hillsdale Boulevard, Suite 250
Foster City, CA
94404
United States

Top Peers

SYMBOLLASTCHG%CHG
SANA
Sana Biotechnology Inc
7.56+0.06+0.80%
DYN
Dyne Therapeutics Inc
26.00+0.05+0.19%
KROS
Keros Therapeutics Inc
54.27-3.33-5.78%
RCKT
Rocket Pharmaceuticals Inc
22.72-0.61-2.61%
RNA
Avidity Biosciences Inc
25.96-1.14-4.21%